{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:04:14Z","timestamp":1793225054436,"version":"4.5.0"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"18","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lenalidomide and pomalidomide have both been evaluated clinically for their properties as anticancer agents, with lenalidomide being available commercially. We previously reported that both compounds cause cell cycle arrest in Burkitt's lymphoma and multiple myeloma cell lines by increasing the level of p21WAF-1 expression. In the present study, we unravel the molecular mechanism responsible for p21WAF-1 up-regulation using Namalwa cells as a human lymphoma model. We show that the increase of p21WAF-1 expression is regulated at the transcriptional level through a mechanism independent of p53. Using a combination of approaches, we show that several GC-rich binding transcription factors are involved in pomalidomide-mediated up-regulation of p21WAF-1. Furthermore, we report that p21WAF-1 up-regulation is associated with a switch from methylated to acetylated histone H3 on p21WAF-1 promoter. Interestingly, lysine-specific demethylase-1 (LSD1) silencing reduced both pomalidomide and lenalidomide up-regulation of p21WAF-1, suggesting that this histone demethylase is involved in the priming of the p21WAF-1 promoter. Based on our findings, we propose a model in which pomalidomide and lenalidomide modify the chromatin structure of the p21WAF-1 promoter through demethylation and acetylation of H3K9. This effect, mediated via LSD1, provides GC-rich binding transcription factors better access to DNA, followed by recruitment of RNA polymerase II and transcription activation. Taken together, our results provide new insights on the mechanism of action of pomalidomide and lenalidomide in the regulation of gene transcription, imply possible efficacy in p53 mutated and deleted cancer, and suggest new potential clinical uses as an epigenetic therapy. [Cancer Res 2009;69(18):7347\u201356]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-4898","type":"journal-article","created":{"date-parts":[[2009,9,8]],"date-time":"2009-09-08T22:12:33Z","timestamp":1252447953000},"page":"7347-7356","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism"],"prefix":"10.1158","volume":"69","author":[{"given":"Laure","family":"Escoubet-Lozach","sequence":"first","affiliation":[{"name":"1Celgene, San Diego, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Lin","family":"Lin","sequence":"additional","affiliation":[{"name":"1Celgene, San Diego, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Jensen-Pergakes","sequence":"additional","affiliation":[{"name":"1Celgene, San Diego, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A.","family":"Brady","sequence":"additional","affiliation":[{"name":"1Celgene, San Diego, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita K.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"2Celgene Corporation, Summit, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Schafer","sequence":"additional","affiliation":[{"name":"2Celgene Corporation, Summit, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W.","family":"Muller","sequence":"additional","affiliation":[{"name":"2Celgene Corporation, Summit, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Worland","sequence":"additional","affiliation":[{"name":"1Celgene, San Diego, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle W.H.","family":"Chan","sequence":"additional","affiliation":[{"name":"1Celgene, San Diego, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Verhelle","sequence":"additional","affiliation":[{"name":"1Celgene, San Diego, California and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2009,9,14]]},"reference":[{"key":"2022061701350594300_B1","doi-asserted-by":"crossref","unstructured":"Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood\u20082000; 96: 2943\u201350.","DOI":"10.1182\/blood.V96.9.2943"},{"key":"2022061701350594300_B2","doi-asserted-by":"crossref","unstructured":"Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer\u20082004; 4: 314\u201322.","DOI":"10.1038\/nrc1323"},{"key":"2022061701350594300_B3","doi-asserted-by":"crossref","unstructured":"Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-\u03b1. J Immunol\u20081999; 163: 380\u20136.","DOI":"10.4049\/jimmunol.163.1.380"},{"key":"2022061701350594300_B4","doi-asserted-by":"crossref","unstructured":"Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood\u20082001; 98: 210\u20136.","DOI":"10.1182\/blood.V98.1.210"},{"key":"2022061701350594300_B5","doi-asserted-by":"crossref","unstructured":"Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer\u20082002; 87: 1166\u201372.","DOI":"10.1038\/sj.bjc.6600607"},{"key":"2022061701350594300_B6","doi-asserted-by":"crossref","unstructured":"Gandhi AK, Kang J, Naziruddin S, Parton A, Schafer PH, Stirling DI. Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly. Leuk Res\u20082006; 30: 849\u201358.","DOI":"10.1016\/j.leukres.2006.01.010"},{"key":"2022061701350594300_B7","doi-asserted-by":"crossref","unstructured":"List AF. Lenalidomide\u2014the phoenix rises. N Engl J Med\u20082007; 357: 2183\u20136.","DOI":"10.1056\/NEJMe078203"},{"key":"2022061701350594300_B8","doi-asserted-by":"crossref","unstructured":"Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med\u20082007; 357: 2133\u201342.","DOI":"10.1056\/NEJMoa070596"},{"key":"2022061701350594300_B9","doi-asserted-by":"crossref","unstructured":"List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med\u20082005; 352: 549\u201357.","DOI":"10.1056\/NEJMoa041668"},{"key":"2022061701350594300_B10","doi-asserted-by":"crossref","unstructured":"Moutouh-de Parseval LA, Verhelle D, Glezer E, et al. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest\u20082008; 118: 248\u201358.","DOI":"10.1172\/JCI32322"},{"key":"2022061701350594300_B11","doi-asserted-by":"crossref","unstructured":"Verhelle D, Corral LG, Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res\u20082007; 67: 746\u201355.","DOI":"10.1158\/0008-5472.CAN-06-2317"},{"key":"2022061701350594300_B12","doi-asserted-by":"crossref","unstructured":"el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell\u20081993; 75: 817\u201325.","DOI":"10.1016\/0092-8674(93)90500-P"},{"key":"2022061701350594300_B13","unstructured":"el-Deiry WS, Harper JW, O'Connor PM, et al. WAF1\/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res\u20081994; 54: 1169\u201374."},{"key":"2022061701350594300_B14","doi-asserted-by":"crossref","unstructured":"Gartel AL, Tyner AL. Transcriptional regulation of the p21((WAF1\/CIP1)) gene. Exp Cell Res\u20081999; 246: 280\u20139.","DOI":"10.1006\/excr.1998.4319"},{"key":"2022061701350594300_B15","doi-asserted-by":"crossref","unstructured":"Choi BH, Kim CG, Bae YS, Lim Y, Lee YH, Shin SY. p21 Waf1\/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression. Cancer Res\u20082008; 68: 1369\u201377.","DOI":"10.1158\/0008-5472.CAN-07-5222"},{"key":"2022061701350594300_B16","unstructured":"Chen B, He L, Savell VH, Jenkins JJ, Parham DM. Inhibition of the interferon-\u03b3\/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region. Cancer Res\u20082000; 60: 3290\u20138."},{"key":"2022061701350594300_B17","doi-asserted-by":"crossref","unstructured":"Roman-Gomez J, Castillejo JA, Jimenez A, et al. 5\u2032 CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1\/WAF1\/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood\u20082002; 99: 2291\u20136.","DOI":"10.1182\/blood.V99.7.2291"},{"key":"2022061701350594300_B18","doi-asserted-by":"crossref","unstructured":"Sterner DE, Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev\u20082000; 64: 435\u201359.","DOI":"10.1128\/MMBR.64.2.435-459.2000"},{"key":"2022061701350594300_B19","doi-asserted-by":"crossref","unstructured":"Nian H, Delage B, Pinto JT, Dashwood RH. Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis\u20082008; 29: 1816\u201324.","DOI":"10.1093\/carcin\/bgn165"},{"key":"2022061701350594300_B20","unstructured":"Wang LG, Liu XM, Fang Y, et al. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol\u20082008; 33: 375\u201380."},{"key":"2022061701350594300_B21","doi-asserted-by":"crossref","unstructured":"Duan Z, Zarebski A, Montoya-Durango D, Grimes HL, Horwitz M. Gfi1 coordinates epigenetic repression of p21Cip\/WAF1 by recruitment of histone lysine methyltransferase G9a and histone deacetylase 1. Mol Cell Biol\u20082005; 25: 10338\u201351.","DOI":"10.1128\/MCB.25.23.10338-10351.2005"},{"key":"2022061701350594300_B22","doi-asserted-by":"crossref","unstructured":"Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell\u20082004; 119: 941\u201353.","DOI":"10.1016\/j.cell.2004.12.012"},{"key":"2022061701350594300_B23","doi-asserted-by":"crossref","unstructured":"Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature\u20082005; 437: 436\u20139.","DOI":"10.1038\/nature04020"},{"key":"2022061701350594300_B24","doi-asserted-by":"crossref","unstructured":"Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A\u20082005; 102: 15545\u201350.","DOI":"10.1073\/pnas.0506580102"},{"key":"2022061701350594300_B25","doi-asserted-by":"crossref","unstructured":"Xie X, Lu J, Kulbokas EJ, et al. Systematic discovery of regulatory motifs in human promoters and 3\u2032 UTRs by comparison of several mammals. Nature\u20082005; 434: 338\u201345.","DOI":"10.1038\/nature03441"},{"key":"2022061701350594300_B26","doi-asserted-by":"crossref","unstructured":"Labhart P, Karmakar S, Salicru EM, et al. Identification of target genes in breast cancer cells directly regulated by the SRC-3\/AIB1 coactivator. Proc Natl Acad Sci U S A\u20082005; 102: 1339\u201344.","DOI":"10.1073\/pnas.0409578102"},{"key":"2022061701350594300_B27","doi-asserted-by":"crossref","unstructured":"Sawka-Verhelle D, Escoubet-Lozach L, Fong AL, et al. PE-1\/METS, an antiproliferative Ets repressor factor, is induced by CREB-1\/CREM-1 during macrophage differentiation. J Biol Chem\u20082004; 279: 17772\u201384.","DOI":"10.1074\/jbc.M311991200"},{"key":"2022061701350594300_B28","doi-asserted-by":"crossref","unstructured":"Metivier R, Penot G, Hubner MR, et al. Estrogen receptor-\u03b1 directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell\u20082003; 115: 751\u201363.","DOI":"10.1016\/S0092-8674(03)00934-6"},{"key":"2022061701350594300_B29","doi-asserted-by":"crossref","unstructured":"Squazzo SL, O'Geen H, Komashko VM, et al. Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res\u20082006; 16: 890\u2013900.","DOI":"10.1101\/gr.5306606"},{"key":"2022061701350594300_B30","doi-asserted-by":"crossref","unstructured":"Wenz HM, Ramachandra S, O'Connell CD, Atha DH. Identification of known p53 point mutations by capillary electrophoresis using unique mobility profiles in a blinded study. Mutat Res\u20081998; 382: 121\u201332.","DOI":"10.1016\/S1383-5726(98)00004-1"},{"key":"2022061701350594300_B31","doi-asserted-by":"crossref","unstructured":"Lombo F, Menendez N, Salas JA, Mendez C. The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives. Appl Microbiol Biotechnol\u20082006; 73: 1\u201314.","DOI":"10.1007\/s00253-006-0511-6"},{"key":"2022061701350594300_B32","doi-asserted-by":"crossref","unstructured":"Kurdistani SK, Tavazoie S, Grunstein M. Mapping global histone acetylation patterns to gene expression. Cell\u20082004; 117: 721\u201333.","DOI":"10.1016\/j.cell.2004.05.023"},{"key":"2022061701350594300_B33","unstructured":"Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res\u20081994; 22: 3551\u20135."},{"key":"2022061701350594300_B34","doi-asserted-by":"crossref","unstructured":"Weller M. Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res\u20081998; 292: 435\u201345.","DOI":"10.1007\/s004410051072"},{"key":"2022061701350594300_B35","doi-asserted-by":"crossref","unstructured":"El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ\u20082001; 8: 1066\u201375.","DOI":"10.1038\/sj.cdd.4400943"},{"key":"2022061701350594300_B36","unstructured":"O'Connor PM, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn KW. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res\u20081993; 53: 4776\u201380."},{"key":"2022061701350594300_B37","doi-asserted-by":"crossref","unstructured":"Albertini V, Jain A, Vignati S, et al. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Res\u20082006; 34: 1721\u201334.","DOI":"10.1093\/nar\/gkl063"},{"key":"2022061701350594300_B38","doi-asserted-by":"crossref","unstructured":"Bonofiglio D, Qi H, Gabriele S, et al. Peroxisome proliferator-activated receptor \u03b3 inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1\/WAF1 gene in a Sp1-dependent manner. Endocr Relat Cancer\u20082008; 15: 545\u201357.","DOI":"10.1677\/ERC-07-0272"},{"key":"2022061701350594300_B39","doi-asserted-by":"crossref","unstructured":"Wang CH, Tsao YP, Chen HJ, Chen HL, Wang HW, Chen SL. Transcriptional repression of p21((Waf1\/Cip1\/Sdi1)) gene by c-jun through Sp1 site. Biochem Biophys Res Commun\u20082000; 270: 303\u201310.","DOI":"10.1006\/bbrc.2000.2422"},{"key":"2022061701350594300_B40","doi-asserted-by":"crossref","unstructured":"Huang W, Tan D, Wang X, et al. Histone deacetylase 3 represses p15(INK4b) and p21(WAF1\/cip1) transcription by interacting with Sp1. Biochem Biophys Res Commun\u20082006; 339: 165\u201371.","DOI":"10.1016\/j.bbrc.2005.11.010"},{"key":"2022061701350594300_B41","doi-asserted-by":"crossref","unstructured":"Mottet D, Pirotte S, Lamour V, et al. HDAC4 represses p21(WAF1\/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene\u20082009; 28: 243\u201356.","DOI":"10.1038\/onc.2008.371"},{"key":"2022061701350594300_B42","doi-asserted-by":"crossref","unstructured":"Wilson AJ, Byun DS, Nasser S, et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell\u20082008; 19: 4062\u201375.","DOI":"10.1091\/mbc.e08-02-0139"},{"key":"2022061701350594300_B43","doi-asserted-by":"crossref","unstructured":"Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1\/2. Cancer Res\u20082008; 68: 2375\u201383.","DOI":"10.1158\/0008-5472.CAN-07-5807"},{"key":"2022061701350594300_B44","doi-asserted-by":"crossref","unstructured":"Majid S, Kikuno N, Nelles J, et al. Genistein induces the p21WAF1\/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res\u20082008; 68: 2736\u201344.","DOI":"10.1158\/0008-5472.CAN-07-2290"},{"key":"2022061701350594300_B45","doi-asserted-by":"crossref","unstructured":"Kumagai T, Wakimoto N, Yin D, et al. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer\u20082007; 121: 656\u201365.","DOI":"10.1002\/ijc.22558"},{"key":"2022061701350594300_B46","unstructured":"Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther\u20082003; 2: 151\u201363."},{"key":"2022061701350594300_B47","doi-asserted-by":"crossref","unstructured":"Fang Z, Fu Y, Liang Y, et al. Increased expression of integrin \u03b21 subunit enhances p21WAF1\/Cip1 transcription through the Sp1 sites and p300-mediated histone acetylation in human hepatocellular carcinoma cells. J Cell Biochem\u20082007; 101: 654\u201364.","DOI":"10.1002\/jcb.21223"},{"key":"2022061701350594300_B48","doi-asserted-by":"crossref","unstructured":"Garcia-Bassets I, Kwon YS, Telese F, et al. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell\u20082007; 128: 505\u201318.","DOI":"10.1016\/j.cell.2006.12.038"},{"key":"2022061701350594300_B49","doi-asserted-by":"crossref","unstructured":"Scoumanne A, Chen X. The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners. J Biol Chem\u20082007; 282: 15471\u20135.","DOI":"10.1074\/jbc.M701023200"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/18\/7347\/2613896\/7347.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/18\/7347\/2613896\/7347.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T13:00:25Z","timestamp":1685106025000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/69\/18\/7347\/549927\/Pomalidomide-and-Lenalidomide-Induce-p21WAF-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,14]]},"references-count":49,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2009,9,14]]},"published-print":{"date-parts":[[2009,9,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-4898","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22377470","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22377470.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6498596.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22377467","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22377467.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6498596","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,14]]}}}